Why this trial matters: First large Phase III evidence of biopsy-confirmed histologic benefit with a metabolic drug in MASH Demonstrates semaglutides impact beyond weight loss to disease-modifying liver effects Supports expanding GLP-1 therapeutics into liver disease care amid a high unmet need Ianalumab Meets Endpoints in Phase III Sjgrens Disease Trials (NEPTUNUS-1 & 2) Novartis reported that both Phase III studies of ianalumab achieved their primary endpoints in patients with Sjgrens disease, offering the first targeted therapy with statistically significant disease activity reduction in this chronic autoimmune disorder
Temperature excursions above 8C denature the peptide structure irreversiblya concern for athletes traveling or storing peptides in gym bags
By delivering vitamin B12 directly through the nasal mucosa, it ensures efficient absorption into the bloodstream, helping prevent complications like anemia and neurological disorders related to B12 deficiency
They naturally occur in the body and play crucial roles in many biological functions, including hormone production, tissue repair, and immune response
Does it contain a pharmaceutical DHT blocker
For about a month, Becerra injected half a milligram a week